Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Descriptive Study of the Efficacy and Safety of CUBICIN (Daptomycin) Under Conditions of Actual Use in the Philippines

NCT01219114 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01219114
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01219114 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Descriptive Study of the Efficacy and Safety of CUBICIN (Daptomycin) Under Conditions of Actual Use in the Philippines
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Withdrawn
Start date
October 31, 2010
Completion date
November 30, 2013
Enrollment
200 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

complicated skin and skin structure infections and bacteremia including right-sided endocarditis